Neurotech startup Synchron is increasing the production of its flagship brain-computer interface (BCI) in anticipation of commercial demand, nearing the device’s market release. The company recently disclosed its acquisition of a minority equity stake in the German manufacturer Acquandas, renowned for its unique ability to layer metals, a crucial component of Synchron’s implant.
Under the agreement, Synchron gains exclusive access to Acquandas’ layering technology for medical devices, and its CEO Tom Oxley and CTO Riki Banerjee will join the manufacturer’s board. The Synchron Switch, a stent-like BCI inserted through blood vessels, enables individuals with limited physical mobility to control technology using their minds. The company has successfully implanted the device in several patients in the U.S. and Australia during initial studies.
To secure broader approval from the U.S. Food and Drug Administration, Synchron plans additional trials to demonstrate the safety and efficacy of its BCI. The official partnership with Acquandas reinforces Synchron’s commitment to innovation in implantable neurotechnology and scaling production to address a significant unmet need for individuals with paralysis.
Although specific details about the equity stake and device production numbers remain undisclosed, Synchron is actively seeking interest from prospective patients. The company aims to launch a patient registry in mid-February to keep individuals with limb or motor impairment informed about trials and gather insights into their needs.
Despite the challenging journey ahead, Synchron has attracted attention from influential investors, including Microsoft co-founder Bill Gates and Amazon founder Jeff Bezos. Elon Musk, CEO of Tesla and SpaceX and owner of Neuralink, has shown interest, raising questions about Synchron during a meeting with Neuralink executives in 2022.
Unlike Neuralink’s invasive brain surgery approach, Synchron’s less-invasive method involves the Stentrode, a stent with embedded sensors delivered to a large vein next to the motor cortex. Although the quality of brain signals may not be as strong as with Neuralink’s direct brain tissue insertion, Synchron believes the minimally invasive procedure will enhance accessibility.
As Synchron accelerates manufacturing, the company is poised to shape the future of neurotechnology and address the pressing needs of individuals with paralysis.
